CRF Health's TrialMax ePRO Instrument Achieves Validation Standard
CRF Health, the developer of the TrialMax® Suite of electronic Clinical Outcome Assessment Solutions (eCOA) for the life sciences industry, becomes the first eCOA company to complete a full validation study for Professor Juniper’s ACQ and AQLQ questionnaires to the “Gold Standard” based on her recently released “Levels of Acceptability of Electronic Versions” rating system. CRF Health continually collaborates with instrument authors to achieve the highest level of compliance with their instruments to assure data integrity.
CRF Health has now deployed spirometer integration together with the ACQ and AQLQ in several global studies on TrialMax Touch™ and TrialMax Slate™ with four major Pharmaceutical companies. Including these programs, CRF Health’s clinical reach and breadth using Professor Juniper’s instruments spans nearly 40 countries, 3000 patients, and more than 40 languages. In addition to these, CRF Health has deployed a further 15 studies using Professor Juniper’s ACQ and AQLQ instruments (but without spirometer integration).
TrialMax® solutions are available for 5 platforms including Windows, Windows Mobile, Android, Palm OS and Web, thus allowing clients to select the right platform, technology and hardware to support their clinical trials. The combination of CRF Health’s clinical expertise and innovation of ePRO collection methods, combined with patient engagement and retention tools, offer new ways to improve study execution and subject compliance.
In a recent study discussion, Professor Elizabeth Juniper commented, “I feel it is important, when evaluating a new technology device to determine whether it will give valid data, to keep in mind that validity is more likely to be achieved if the screen shots are similar to the original format especially when translating languages with longer text.”
“Professor Elizabeth Juniper’s diligence and research integrity is a model for the industry. We are excited to have had the opportunity to collaborate and to jointly achieve this industry milestone. It is through our engagement with researchers and instrument authors such as Professor Elizabeth Juniper that we continually enhance our regulatory rigor, technology competence and patient research integrity through clinical expertise and innovation,” commented Rachael Wyllie, CEO of CRF Health.
Related Links:
CRF Health’s TrialMax ePRO is Recognized as Medical Device
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
